生物试剂
>
生化试剂
>
信号通路
> 双醋酚丁
加入收藏 取消收藏

双醋酚丁  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：10mg 50mg 100mg 250mg 1g in glass bottle
溶解性：溶于DMSO（100 mg/mL 超声）
产品描述：基本信息 产品编号：O10220 产品名称：Oxyphenisatin acetate CAS: 115-33-3   储存条件 粉末 -20℃ 四年     分子式： C24H19NO5 溶于液体 -80℃ 六个月 分子量 401.41 -20℃ 一个月 化学名：  4-(3-(4-(Acetyloxy)phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)phenyl acetate   Solubility (25°C)   体外 DMSO 100mg/mL (249.12mM; Need ultrasonic) Ethanol   Water   体内 现配现用   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.4912mL 12.4561mL 24.9122mL 5mM 0.4982mL 2.4912mL 4.9824mL 10mM 0.2491mL 1.2456mL 2.4912mL   生物活性 产品描述 一种oxyphenisatin的前体药物。 靶点/IC50 Autophagy   体外研究 Oxyphenisatin acetate inhibits the growth of the breast cancer cell lines MCF7, T47D, HS578T, and MDA-MB-468. In the estrogen receptor (ER) positive MCF7 and T47D cells, oxyphenisatin acetate induces TNFα expression and TNFR1 degradation, indicating autocrine receptor-mediated apoptosis in these lines. Ten micromoles per liter Oxyphenisatin acetate treatment results in autophagy and mitochondrial dysfunction.   体内研究 Oxyphenisatin acetate (300mg/kg, i.p.) delivers intraperitoneally inhibited tumor growth, accompanied by phosphorylation of eIF2α and degradation of TNFR1 in an MCF7 xenograft model.   推荐实验方法(仅供参考) 动物实验:   Animal Administration Assessment in several other tumor models demonstrates tolerability with oxyphenisatin acetate at 300mg/kg given once daily or 200mg/kg given twice daily. For the MCF-7 study treatments are administered on an exact body weight basis using dose volumes of 1-2mL/kg body weight. The vehicle control receives 100% DMSO. The treated group receives 300 mg/kg oxyphenisatin acetate once daily for a total of 10 days, followed by a 3 day rest and an additional 6 days of dosing. The dose solutions are prepared in 100% DMSO, aliquoted and stored frozen until used. The mice are monitored for a total of 52 days with treatment initiation occurring on day 27 posttumor implantation.
保存条件：-20℃

猜你喜欢